Journal of Inherited Metabolic Disease

Papers
(The TQCC of Journal of Inherited Metabolic Disease is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I56
Endocannabinoid receptor 2 is a potential biomarker and therapeutic target for the lysosomal storage disorders49
New mouse models with hypomorphic SUMF1 variants mimic attenuated forms of multiple sulfatase deficiency49
Uncommon case of mitochondrial disease: Mild amyotrophy of the legs and symmetrical lipomatosis of the arms48
Long‐term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II41
The clinical utility in hospital‐wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA‐related disorders39
Isovaleric aciduria identified by newborn screening: Strategies to predict disease severity and stratify treatment39
MOGS‐CDG: Quantitative analysis of the diagnostic Glc3Man tetrasaccharide and clinical spectrum of six new cases38
Long‐term anthropometric development of individuals with inherited metabolic diseases identified by newborn screening35
Metabolomics analysis of antiquitin deficiency in cultured human cells and plasma: Relevance to pyridoxine‐dependent epilepsy32
Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate30
The impact of liver transplantation on health‐related quality of life in (acute) intoxication‐type inborn errors of metabolism30
Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria28
AAV‐mediated expression of galactose‐1‐phosphate uridyltransferase corrects defects of galactose metabolism in classic galactosemia patient fibroblasts28
Towards values‐based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders25
Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities25
25
Guidelines in the JIMD: Evidence‐based practice for inherited metabolic disease22
Mucopolysaccharidoses type I gene therapy22
Inborn errors of metabolism and their impact in paediatric dentistry22
Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study22
Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late‐onset Pompe disease22
Mild/moderate phenotypes in AADC deficiency: Focus on the aromatic amino acid decarboxylase protein22
22
Altered neural oscillations in classical galactosaemia during sentence production20
Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients20
Ornithine transcarbamylase deficiency: A diagnostic odyssey20
Glutaminase 2 knockdown reduces hyperammonemia and associated lethality of urea cycle disorder mouse model20
Tyrosine hydroxylase variants influence protein expression, cellular localization, stability, enzymatic activity and the physical interaction between tyrosine hydroxylase and GTP cyclohydrolase 119
The role of ERNDIM diagnostic proficiency schemes in improving the quality of diagnostic testing for inherited metabolic diseases19
Propionic Acidemia‐Induced Proarrhythmic Electrophysiological Alterations in Human iPSC‐Derived Cardiomyocytes17
Potential therapeutic uses of L‐citrulline beyond genetic urea cycle disorders17
A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies17
The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin‐deficient cells17
Gene therapy for mitochondrial disorders16
Brain morphometry in hepatic Wilson disease patients16
Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value‐based healthcare approach and systematic benefit‐risk assessment16
A 6‐month randomized controlled trial for vitamin E supplementation in pediatric patients with Gaucher disease: Effect on oxidative stress, disease severity and hepatic complications16
Cognitive impairment in children and adults with cerebrotendinous xanthomatosis: A French cohort study16
Phosphoinositide Metabolism: Biochemistry, Physiology and Genetic Disorders16
Valine Restriction Extends Survival in a Drosophila Model of Short‐Chain Enoyl‐CoA Hydratase 1 (ECHS1) Deficiency16
16
Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia15
Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 115
The role of PGM1isoform 2 in PGM1‐CDG: One step closer to genotype–phenotype correlation?15
Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism15
Performance of Relative Exchangeable Copper for the Diagnosis of Wilson Disease in Acute Liver Failure15
Subdural hematoma in glutaric aciduria type 1: High excreters are prone to incidental SDH despite newborn screening14
Adherence to treatment, a challenge even in treatable metabolic rare diseases: A cross sectional study of Wilson's disease14
Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study14
Muscle‐specific, liver‐detargeted adeno‐associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa−/− mice14
Multi‐omics in classical galactosemia: Evidence for the involvement of multiple metabolic pathways14
A promoter variant in theOTCgene associated with late and variable age of onset hyperammonemia14
Succinic semialdehyde dehydrogenase deficiency in mice and in humans: An untargeted metabolomics perspective14
Abnormal concentrations of acetylated amino acids in cerebrospinal fluid in acetyl‐CoA transporter deficiency14
Cellular mechanisms of acute rhabdomyolysis in inherited metabolic diseases14
A phenylalanine‐free recombinant nutritional protein for the dietary management of phenylketonuria14
Physical training and high‐protein diet improved muscle strength, parent‐reported fatigue, and physical quality of life in children with Pompe disease14
Issue Information14
On pathways and blind alleys—The importance of biomarkers in vitamin B6‐dependent epilepsies13
Speech, Language and Non‐verbal Communication in CLN2 and CLN3 Batten Disease13
Issue Information13
Conserved quality control mechanisms of mitochondrial protein import13
Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders13
13
Phenotype and genotype of 197 British patients with McArdle disease: An observational single‐centre study13
Impaired coenzyme A homeostasis in cardiac dysfunction and benefits of boosting coenzyme A production with vitamin B5 and its derivatives in the management of heart fa12
Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment‐specific detoxification of glyoxylate12
12
Patents vs patients 1‐0: The case of chenodeoxycholic acid12
Issue Information12
Letter to the editor in response to Betzler et al.12
Patient‐initiated conference focuses on bridging gaps between patients, clinicians and scientists in the field of rare neurotransmitter‐related disorders12
Mitochondrial RNA processing defect caused by a SUPV3L1 mutation in two siblings with a novel neurodegenerative syndrome12
NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model12
Reversible white matter changes following a 4‐week high phenylalanine exposure in adults with phenylketonuria12
Gene expression changes in Tay–Sachs disease begin early in fetal brain development12
SSIEM 2022 Annual Symposium in Freiburg, Germany12
Obituary for Charles Rider Roe, MD12
12
Gene therapy for glycogen storage diseases11
Issue Information11
Circulatory response to exercise relative to oxygen uptake assessed in the follow‐up of patients with fatty acid beta‐oxidation disorders11
Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency11
The potential and limitations of intrahepatic cholangiocyte organoids to study inborn errors of metabolism11
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil11
Corrigendum11
News from Valencia: JIMD themed issue on ureagenesis defects and allied disorders11
Progression of Spinal Cord Disease in Adult Men With Adrenoleukodystrophy11
Acute intermittent porphyria, givosiran, and homocysteine11
State‐of‐the‐art 2023 on gene therapy for phenylketonuria11
11
Inborn Errors of Cell Trafficking and Complex Lipids: A Further Step in Redefining Hereditary Metabolic Disorders11
Protein requirements in adults with phenylketonuria and bioavailability of glycomacropeptide compared to an l‐amino acid‐based product11
Postauthorization safety study of betaine anhydrous11
Patterns of Penetrance and Expressivity of Long‐Term Outcomes in Classic Galactosemia11
10
High dose genistein in Sanfilippo syndrome: A randomised controlled trial10
Influence of early identification and therapy on long‐term outcomes in early‐onset MTHFR deficiency10
Global loss of bone, muscle, and fat mass in a patient with juvenile Paget disease (hereditary hyperphosphatasia)10
Normothermic Machine Perfusion of Explanted Human Metabolic Livers: A Proof of Concept for Studying Inborn Errors of Metabolism10
Neonatal presentation of occipital horn syndrome caused by a ATP7A missense variant10
Experimental models of Barth syndrome10
Eye movement disorders in inborn errors of metabolism: A quantitative analysis of 37 patients10
Severe neuromuscular forms of glycogen storage disease type IV: Histological, clinical, biochemical, and molecular findings in a large French case series9
Neurologic outcome following liver transplantation for methylmalonic aciduria9
Homocysteine metabolites inhibit autophagy, elevate amyloid beta, and induce neuropathy by impairing Phf8/H4K20me1‐dependent epigenetic regulation of mTOR in cystathionine β‐synt9
Addition of galactose‐1‐phosphate measurement enhances newborn screening for classical galactosemia9
9
Issue Information9
Clinical presentation and natural history of Barth Syndrome: An overview9
Issue Information9
Impact of measuring heteroplasmy of a pathogenic mitochondrial DNA variant at the single‐cell level in individuals with mitochondrial disease9
Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria9
Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network9
Neurotransmitters … it is all about communication!9
Quantitative brain morphometry identifies cerebellar, cortical, and subcortical gray and white matter atrophy in late‐onset Tay‐Sachs disease9
Development of a novel tool for individual treatment trials in mucopolysaccharidosis8
Abstracts8
Beyond neuropsychological tests: AI speech analysis in PKU8
Navigating the rare neurotransmitter disease diagnosis: Insights from patients and health care professionals8
Pathological variants in nuclear genes causing mitochondrial complex III deficiency: An update8
Clinical pharmacology considerations for first‐in‐human clinical trials for enzyme replacement therapy8
A new D‐galactose treatment monitoring index for PGM1‐CDG8
Levodopa‐refractory hyperprolactinemia and pituitary findings in inherited disorders of biogenic amine metabolism8
Very long‐term outcomes in 23 patients with cblA type methylmalonic acidemia8
An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio8
A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management8
The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease8
Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study8
Adult‐onset diagnosis of urea cycle disorders: Results of a French cohort of 71 patients8
Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships8
0.10377788543701